Fengmin Zhao
Overview
Explore the profile of Fengmin Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider B, Zhao F, Ballinger T, Garcia S, Shen F, Virani S, et al.
J Clin Oncol
. 2024 Jun;
42(24):2899-2907.
PMID: 38828938
Purpose: Black women experience higher rates of taxane-induced peripheral neuropathy (TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for early-stage breast cancer, leading to more dose reductions...
2.
Peipert J, Zhao F, Lee J, Shen S, Ip E, OConnell N, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e243854.
PMID: 38536173
Importance: There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs). Objective: To examine whether a PRO question, item 5 from the Functional...
3.
Smith K, Zhao F, Mayer I, Tevaarwerk A, Garcia S, Arteaga C, et al.
Cancer
. 2024 Jan;
130(10):1747-1757.
PMID: 38236702
Background: Patient-reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment-associated adverse events (AEs) compared with clinician-rated AEs. The authors present PROs assessing...
4.
OConnell N, Zhao F, Lee J, Ip E, Peipert J, Graham N, et al.
J Clin Oncol
. 2023 Oct;
42(3):266-272.
PMID: 37801678
Purpose: Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are...
5.
Ballinger T, Marques H, Xue G, Hoffman R, Gatsonis C, Zhao F, et al.
J Natl Compr Canc Netw
. 2023 Sep;
21(9):915-923.e1.
PMID: 37673107
Background: Observational data investigating the relationship between body habitus and outcomes in breast cancer have been variable and inconsistent, largely centered in the curative setting and focused on weight-based metrics....
6.
Peipert J, Shaunfield S, Kaiser K, Moreno P, Fox R, Kircher S, et al.
Support Care Cancer
. 2023 Jul;
31(8):489.
PMID: 37486453
No abstract available.
7.
Peipert J, Shaunfield S, Kaiser K, Moreno P, Fox R, Kircher S, et al.
Support Care Cancer
. 2022 Dec;
31(1):37.
PMID: 36525100
Background: There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item ("I am bothered by side effects of treatment") is...
8.
Unger J, LeBlanc M, George S, Wolmark N, Curran Jr W, ODwyer P, et al.
J Clin Oncol
. 2022 Dec;
41(11):2020-2028.
PMID: 36480773
Purpose: In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all...
9.
Kemeny M, Zhao F, Forastiere A, Catalano P, Hamilton S, Miedema B, et al.
Ann Surg Oncol
. 2022 Oct;
30(2):1099-1109.
PMID: 36305992
Background: Studies suggest that adjuvant chemotherapy should be initiated at the earliest possible time. The Eastern Cooperative Oncology Group (ECOG) and Intergroup evaluated the effect of perioperative fluorouracil (5-FU) on...
10.
Khan S, Zhao F, Goldstein L, Sparano J, Sledge G
J Clin Oncol
. 2022 Jul;
40(33):3899-3901.
PMID: 35820109
No abstract available.